<DOC>
	<DOCNO>NCT01897779</DOCNO>
	<brief_summary>RPX7009 ( beta-lactamase inhibitor ) study combination carbapenem ( RPX2014 ) treat bacterial infection , include due multi-drug resistant bacteria .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Intravenous RPX2014 RPX7009 Healthy Adult Subjects</brief_title>
	<detailed_description>The worldwide spread resistance antibiotic among Gram-negative bacteria , particularly member ESKAPE group pathogen , result crisis treatment hospital acquire infection . In particular , recent dissemination serine carbapenemase ( e.g. , KPC ) Enterobacteriaceae US hospital pose considerable threat carbapenems member beta-lactam class antimicrobial agent . Rempex develop fix combination antibiotic carbapenem ( RPX2014 ) plus new beta-lactamase inhibitor ( RPX7009 ) activity serine beta-lactamase , include KPC . This Phase 1 study ass safety , tolerability pharmacokinetics intravenous RPX2014 RPX7009 , administer alone combination , healthy adult subject .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>beta-Lactamase Inhibitors</mesh_term>
	<criteria>1 . Healthy adult male female , 18 55 year age ( inclusive ) time screen . 2 . Body mass index ( BMI ) ≥ 18.5 ≤ 29.9 ( kg/m2 ) weight 55.0 100.0 kg ( inclusive ) . 3 . Medically healthy clinically insignificant screen result ( e.g. , laboratory profile , medical history , ECGs , physical examination ) deem PI . 4 . Nontobacco/nicotinecontaining product user minimum Dose Study 6 month prior Day 1 . 5 . Voluntarily consent participate study . 6 . Sexually abstinent agree use two approve method contraception . 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease . 2 . Positive urine drug/alcohol test screen checkin ( Day 1 ) . 3 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) . 4 . History presence alcoholism drug abuse within 2 year prior Day 1 . 5 . Use overthecounter ( OTC ) medication , include herbal product vitamin , within 7 day prior Day 1 . Up 2 gram per day acetaminophen allow acute event discretion PI . 6 . Blood donation significant blood loss ( i.e. , &gt; 500 mL ) within 56 day prior Day 1 . 7 . Plasma donation within 7 day prior Day 1 . 8 . Participation another investigational clinical trial within 30 day prior Day 1 . 9 . Subjects abnormalities laboratory value screen checkin ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>